Piperazine derivatives with central pharmacological activity used as therapeutic tools
Medicinal chemistry is a science applied to the search and discovery of new therapeutic agents for the treatment of various diseases. Therefore, promising structures have been identified; one of these structures is the piperazine moiety, a cyclic molecule containing two nitrogen atoms in positions 1...
Saved in:
| Published in | Fundamental & clinical pharmacology Vol. 33; no. 1; pp. 13 - 24 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.02.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0767-3981 1472-8206 1472-8206 |
| DOI | 10.1111/fcp.12408 |
Cover
Loading…
| Abstract | Medicinal chemistry is a science applied to the search and discovery of new therapeutic agents for the treatment of various diseases. Therefore, promising structures have been identified; one of these structures is the piperazine moiety, a cyclic molecule containing two nitrogen atoms in positions 1 and 4 as well as four carbon atoms. Many piperazine derivatives have central pharmacological activity that mainly involves the activation of the monoamine pathway. Thus, piperazine derivatives have been the subject of research for many central therapeutic applications, including antipsychotic, antidepressant and anxiolytic applications. Benzylpiperazine is the prototype of piperazine derivatives; this substance is the main component of recreational drugs, partly due to its stimulant and euphoric effects. This paper describes some piperazine derivatives used therapeutically as antipsychotic (clozapine), antidepressant (vortioxetine) and anxiolytic (buspirone) drugs. |
|---|---|
| AbstractList | Medicinal chemistry is a science applied to the search and discovery of new therapeutic agents for the treatment of various diseases. Therefore, promising structures have been identified; one of these structures is the piperazine moiety, a cyclic molecule containing two nitrogen atoms in positions 1 and 4 as well as four carbon atoms. Many piperazine derivatives have central pharmacological activity that mainly involves the activation of the monoamine pathway. Thus, piperazine derivatives have been the subject of research for many central therapeutic applications, including antipsychotic, antidepressant and anxiolytic applications. Benzylpiperazine is the prototype of piperazine derivatives; this substance is the main component of recreational drugs, partly due to its stimulant and euphoric effects. This paper describes some piperazine derivatives used therapeutically as antipsychotic (clozapine), antidepressant (vortioxetine) and anxiolytic (buspirone) drugs. Medicinal chemistry is a science applied to the search and discovery of new therapeutic agents for the treatment of various diseases. Therefore, promising structures have been identified; one of these structures is the piperazine moiety, a cyclic molecule containing two nitrogen atoms in positions 1 and 4 as well as four carbon atoms. Many piperazine derivatives have central pharmacological activity that mainly involves the activation of the monoamine pathway. Thus, piperazine derivatives have been the subject of research for many central therapeutic applications, including antipsychotic, antidepressant and anxiolytic applications. Benzylpiperazine is the prototype of piperazine derivatives; this substance is the main component of recreational drugs, partly due to its stimulant and euphoric effects. This paper describes some piperazine derivatives used therapeutically as antipsychotic (clozapine), antidepressant (vortioxetine) and anxiolytic (buspirone) drugs.Medicinal chemistry is a science applied to the search and discovery of new therapeutic agents for the treatment of various diseases. Therefore, promising structures have been identified; one of these structures is the piperazine moiety, a cyclic molecule containing two nitrogen atoms in positions 1 and 4 as well as four carbon atoms. Many piperazine derivatives have central pharmacological activity that mainly involves the activation of the monoamine pathway. Thus, piperazine derivatives have been the subject of research for many central therapeutic applications, including antipsychotic, antidepressant and anxiolytic applications. Benzylpiperazine is the prototype of piperazine derivatives; this substance is the main component of recreational drugs, partly due to its stimulant and euphoric effects. This paper describes some piperazine derivatives used therapeutically as antipsychotic (clozapine), antidepressant (vortioxetine) and anxiolytic (buspirone) drugs. |
| Author | Moreira, Lorrane K. S. Brito, Adriane F. Menegatti, Ricardo Costa, Elson A. |
| Author_xml | – sequence: 1 givenname: Adriane F. surname: Brito fullname: Brito, Adriane F. organization: Federal University of Goiás – sequence: 2 givenname: Lorrane K. S. surname: Moreira fullname: Moreira, Lorrane K. S. organization: Federal University of Goiás – sequence: 3 givenname: Ricardo surname: Menegatti fullname: Menegatti, Ricardo organization: Federal University of Goiás – sequence: 4 givenname: Elson A. orcidid: 0000-0003-1996-0901 surname: Costa fullname: Costa, Elson A. email: xico@ufg.br organization: Federal University of Goiás |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30151922$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90ctKxDAUBuAgio6XhS8gBTe6qObSJu1SBm8g6ELdhjQ5dSKdpibpyPj0RkddCJpNCHznEP5_G633rgeE9gk-Iemctno4IbTA1RqakELQvKKYr6MJFlzkrK7IFtoO4RljIjDhm2iLYVKSmtIJeryzA3j1ZnvIDHi7UNEuIGSvNs4yDX30qsuGmfJzpV3nnqxOb6UTsnGZjQFMpkIWZ2nHAGO0OovOdWEXbbSqC7D3de-gh4vz--lVfnN7eT09u8k1K1mVE2FIrXmhmG6EbhtTKxC6ZlRwSgvSYMVVyxRnBRjWGFxXrCRNRUzbGl3iiu2go9XewbuXEUKUcxs0dJ3qwY1BUlyXJeW8YIke_qLPbvR9-p2khFdCMCGKpA6-1NjMwcjB27nyS_mdWALHK6C9C8FD-0MIlh9tyNSG_Gwj2dNfVtuYAnYfsdruv4lX28Hy79XyYnq3mngHkTabNQ |
| CitedBy_id | crossref_primary_10_3987_REV_22_SR_R_6 crossref_primary_10_1016_j_arabjc_2023_105292 crossref_primary_10_1107_S2056989019012702 crossref_primary_10_3390_biomedicines11102739 crossref_primary_10_2174_0118756298277743231213065544 crossref_primary_10_2174_1871527320666211112173233 crossref_primary_10_1016_j_molliq_2020_114555 crossref_primary_10_3390_biophysica4040034 crossref_primary_10_1016_j_bioorg_2020_104450 crossref_primary_10_1016_j_bioorg_2020_104496 crossref_primary_10_3390_molecules25081889 crossref_primary_10_1002_ardp_202400071 crossref_primary_10_1002_adsc_202400343 crossref_primary_10_1016_j_forc_2024_100582 crossref_primary_10_3390_ph16010083 crossref_primary_10_1080_00304948_2022_2085994 crossref_primary_10_1007_s00253_020_10678_w crossref_primary_10_1016_j_molstruc_2022_134671 crossref_primary_10_1080_17460441_2022_2103535 crossref_primary_10_1016_j_bioorg_2021_105429 crossref_primary_10_1107_S2056989022008337 crossref_primary_10_1007_s00210_019_01649_8 crossref_primary_10_1007_s00706_021_02872_x crossref_primary_10_1016_j_bmc_2024_117605 crossref_primary_10_1007_s44169_023_00050_0 crossref_primary_10_1016_j_ejmcr_2024_100132 crossref_primary_10_1055_s_0040_1720114 crossref_primary_10_1016_j_algal_2025_103893 crossref_primary_10_1016_j_bmcl_2021_127944 crossref_primary_10_3390_molecules27113419 crossref_primary_10_3390_cryst12121807 crossref_primary_10_1016_j_molstruc_2023_136089 crossref_primary_10_1055_a_1323_2813 crossref_primary_10_1055_s_0042_1751555 crossref_primary_10_1016_j_forc_2022_100416 crossref_primary_10_2174_1573407219666230718105347 crossref_primary_10_1016_j_molstruc_2023_135791 crossref_primary_10_1107_S2056989022011501 crossref_primary_10_2174_0113895575319878240612070850 crossref_primary_10_1002_slct_202400465 crossref_primary_10_1016_j_molstruc_2023_136997 crossref_primary_10_1186_s13765_021_00651_0 crossref_primary_10_3390_ijms242417414 crossref_primary_10_1002_ajoc_202500031 crossref_primary_10_1038_s41598_024_73849_z crossref_primary_10_1107_S2414314620015230 crossref_primary_10_2174_0115734064244117230923172611 crossref_primary_10_1007_s11469_023_01088_w crossref_primary_10_1039_D0OB02243H crossref_primary_10_1002_cmdc_202100045 crossref_primary_10_1080_14756366_2021_1931861 crossref_primary_10_1016_j_molstruc_2023_136193 crossref_primary_10_1007_s11164_022_04921_4 crossref_primary_10_1016_j_tet_2019_130876 crossref_primary_10_1039_D3SM01035J crossref_primary_10_1007_s11172_023_3873_1 crossref_primary_10_1016_j_molstruc_2022_133284 crossref_primary_10_1002_slct_202401683 crossref_primary_10_1007_s11356_021_13320_y crossref_primary_10_1016_j_bmcl_2023_129425 crossref_primary_10_14233_ajchem_2020_22832 crossref_primary_10_1002_bmc_5082 crossref_primary_10_1016_j_bbr_2020_112827 crossref_primary_10_1139_cjpp_2021_0729 crossref_primary_10_1016_j_molstruc_2024_138263 crossref_primary_10_1107_S2056989019010491 crossref_primary_10_1107_S2056989020002844 crossref_primary_10_1016_j_molstruc_2024_139514 crossref_primary_10_1111_fcp_12443 crossref_primary_10_1107_S2056989023002529 crossref_primary_10_1002_ardp_202000486 crossref_primary_10_1016_j_matpr_2024_04_034 crossref_primary_10_1080_10406638_2022_2125992 crossref_primary_10_1016_j_ejmech_2023_115777 crossref_primary_10_1080_1536383X_2021_1873782 |
| Cites_doi | 10.1021/jm00153a010 10.1016/j.bmcl.2004.05.091 10.1111/fcp.12321 10.2174/1386207043328544 10.1016/j.ejmech.2012.08.011 10.1186/1471-244X-14-102 10.1192/bjp.bp.115.177261 10.1111/cbdd.12961 10.1177/0269881107077260 10.1016/j.jep.2016.02.023 10.1021/jm00091a004 10.1007/BF00169129 10.1016/j.drugalcdep.2011.10.007 10.1080/13543776.2016.1189902 10.1007/s00204-013-1057-x 10.1111/fcp.12051 10.1002/j.2051-5545.2010.tb00298.x 10.7439/ijasr.v1i1.1766 10.1016/j.pbb.2008.12.003 10.1016/j.lfs.2015.11.009 10.1016/j.brainres.2010.07.007 10.2174/138955707782331722 10.1155/2013/873278 10.1007/s00210-017-1451-7 10.1016/j.lfs.2012.04.037 10.1016/j.bbr.2012.09.016 |
| ContentType | Journal Article |
| Copyright | 2018 Société Française de Pharmacologie et de Thérapeutique 2018 Société Française de Pharmacologie et de Thérapeutique. Copyright © 2019 Société Française de Pharmacologie et de Thérapeutique |
| Copyright_xml | – notice: 2018 Société Française de Pharmacologie et de Thérapeutique – notice: 2018 Société Française de Pharmacologie et de Thérapeutique. – notice: Copyright © 2019 Société Française de Pharmacologie et de Thérapeutique |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QO 7T7 7U7 7U9 8FD C1K FR3 H94 P64 7X8 |
| DOI | 10.1111/fcp.12408 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE Virology and AIDS Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1472-8206 |
| EndPage | 24 |
| ExternalDocumentID | 30151922 10_1111_fcp_12408 FCP12408 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- --K .3N .GA .GJ .Y3 05W 0R~ 10A 1B1 1OB 1OC 29H 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA GWYGA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NQ- O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIG RIWAO RJQFR ROL RPZ RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YCJ YFH ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7QO 7T7 7U7 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 P64 7X8 |
| ID | FETCH-LOGICAL-c3538-17d19c64a3cb7cfbd9ae7c932762241b0a6af3a634ed3bd098351b81dffdc5083 |
| IEDL.DBID | DR2 |
| ISSN | 0767-3981 1472-8206 |
| IngestDate | Thu Jul 10 23:52:15 EDT 2025 Sat Jul 26 02:23:32 EDT 2025 Thu Apr 03 07:05:39 EDT 2025 Tue Jul 01 03:36:36 EDT 2025 Thu Apr 24 22:51:37 EDT 2025 Wed Jan 22 16:27:49 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Antidepressant Medicinal chemistry Neuropharmacology Anxiolytic |
| Language | English |
| License | 2018 Société Française de Pharmacologie et de Thérapeutique. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3538-17d19c64a3cb7cfbd9ae7c932762241b0a6af3a634ed3bd098351b81dffdc5083 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-1996-0901 |
| PMID | 30151922 |
| PQID | 2168773774 |
| PQPubID | 2045155 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2095526643 proquest_journals_2168773774 pubmed_primary_30151922 crossref_primary_10_1111_fcp_12408 crossref_citationtrail_10_1111_fcp_12408 wiley_primary_10_1111_fcp_12408_FCP12408 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2019 2019-02-00 2019-Feb 20190201 |
| PublicationDateYYYYMMDD | 2019-02-01 |
| PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Hoboken |
| PublicationTitle | Fundamental & clinical pharmacology |
| PublicationTitleAlternate | Fundam Clin Pharmacol |
| PublicationYear | 2019 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 1 2015; 6 2012; 122 2011; 2 2016; 209 2013; 87 2013; 62 1995; 35 2004; 7 2015; 143 2014; 28 2010; 1352 2016; 184 2018; 391 2012; 90 2017; 90 2009; 92 2013; 2013 1987; 335 2004; 14 2013; 237 1986; 29 2014; 14 2007; 7 2016 2015; 91 2007; 21 2018; 32 2016; 26 2010; 9 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_15_1 Locke A.B. (e_1_2_7_27_1) 2015; 91 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_28_1 e_1_2_7_29_1 Singh K. (e_1_2_7_32_1) 2015; 6 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_20_1 Amita T. (e_1_2_7_2_1) 2011; 2 |
| References_xml | – volume: 7 start-page: 1108 year: 2007 end-page: 1119 article-title: Privileged structures: a useful concept for the rational design of new lead drug candidates publication-title: Mini Rev. Med. Chem. – volume: 62 start-page: 214 year: 2013 end-page: 221 article-title: Biotransformation of LASSBio‐579 and pharmacological evaluation of p‐hydroxylated metabolite a N‐phenylpiperazine antipsychotic lead compound publication-title: Eur. J. Med. Chem. – volume: 335 start-page: 588 year: 1987 end-page: 592 article-title: Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5‐HT receptors negatively coupled with adenylate cyclase in hippocampal neurons publication-title: Nauny‐Schimiedebergs Arch. Pharmacol. – volume: 122 start-page: 174 year: 2012 end-page: 185 article-title: Piperazine compounds as drugs of abuse publication-title: Drug Alcohol Depend. – volume: 391 start-page: 255 year: 2018 end-page: 269 article-title: A new piperazine derivative: 1‐(4‐(3, 5‐di‐tert‐butyl‐4‐hydroxybenzyl) piperazin‐1‐yl)‐2‐methoxyethan‐1‐one with antioxidant and central activity publication-title: Naunyn‐Schmiedeberg's Arch. Pharmacol. – volume: 87 start-page: 929 year: 2013 end-page: 947 article-title: Update on 1‐benzylpiperazine (BZP) party pills publication-title: Arch. Toxicol. – volume: 35 start-page: 2369 year: 1995 end-page: 2374 article-title: Structure‐activity relationship studies of central nervous system agents. 5. Effect of the hydrocarbon chain on the affinity of 4‐substituted 1‐(3‐chlorophenyl) piperazine for 5‐HT1A receptor site publication-title: J. Med. Chem. – volume: 91 start-page: 617 year: 2015 end-page: 624 article-title: Diagnosis and management of generalized anxiety disorder and panic disorder in adults publication-title: Am. Fam. Physician – volume: 90 start-page: 432 year: 2017 end-page: 442 article-title: Anxiolytic‐like effect of 2‐(4‐((1‐phenyl‐1H‐pyrazol‐4‐yl) methyl) piperazin‐1‐yl) ethan‐1‐ol is mediated through the benzodiazepine and nicotinic pathways publication-title: Chem. Biol. Drug Des. – volume: 14 start-page: 4287 year: 2004 end-page: 4290 article-title: Antioxidantive activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter publication-title: Bioorg. Med. Chem. Lett. – volume: 21 start-page: 888 year: 2007 end-page: 894 article-title: Review: Benzylpiperazine: a drug of abuse? publication-title: J. Psychopharmacol. – volume: 14 start-page: 102 year: 2014 article-title: Clozapine: a review of clinical practice guidelines and prescribing trends publication-title: BMC Psychiatry – volume: 92 start-page: 243 year: 2009 end-page: 250 article-title: A comparison of 1‐benzylpiperazine and methamphetamine in their acute effects on anxiety‐related behavior of hooded rats publication-title: Pharmacol. Biochem. Behav. – volume: 2 start-page: 1547 year: 2011 end-page: 1548 article-title: Piperazine: the molecule of diverse pharmacological importance publication-title: Int. J. Res. Ayurved. Pharm. – volume: 1352 start-page: 167 year: 2010 end-page: 175 article-title: GABAergic and nitriergic modulation by curcumin for its antianxiety‐like activity in mice publication-title: Brain Res. – year: 2016 – volume: 7 start-page: 473 year: 2004 end-page: 493 article-title: Privileged Structures: applications in drug discovery publication-title: Comb. Chem. High Throughput Screen. – volume: 2013 start-page: 873278 year: 2013 article-title: Neurobiology of major depressive disorder publication-title: Neural. Plast. – volume: 29 start-page: 359 year: 1986 end-page: 369 article-title: Synthesis and biological evaluation of 1‐(1,2‐Benzisothiazol‐3‐yl) ‐and (1,2‐Benzisoxazol‐3‐yl) piperazine derivatives as potential antipsychotic agents publication-title: J. Med. Chem. – volume: 32 start-page: 114 year: 2018 end-page: 0119 article-title: Atropinic (anticholinergic) burden in antipsychotic‐treated patients publication-title: Fundam. Clin. Pharmacol. – volume: 209 start-page: 385 year: 2016 end-page: 392 article-title: Clozapine v. first‐and second‐generation antipsychotics in treatment‐refractory schizophrenia: systematic review and meta‐analysis publication-title: Br. J. Psychiatry – volume: 143 start-page: 187 year: 2015 end-page: 193 article-title: Involvement of the monoamine system in antidepressant‐like properties of 4‐(1‐phenyl‐1 h‐pyrazol‐4‐ylmethyl)‐piperazine‐1‐carboxylic acid ethyl ester publication-title: Life Sci. – volume: 6 start-page: 4145 year: 2015 article-title: Piperazine ‐ A biologically active scaffold publication-title: Int. J. Pharm. Sci. Res. – volume: 90 start-page: 910 year: 2012 end-page: 916 article-title: Central pharmacological activity of a new piperazine derivative: 4‐(1‐Phenyl‐1 h‐pyrazol‐4‐ylmethyl)‐piperazine‐1‐carboxylic acid ethyl ester publication-title: Life Sci. – volume: 1 start-page: 5 year: 2015 end-page: 11 article-title: Piperazine and Pyrazine containing molecules and their diverse pharmacological activities publication-title: Int. J. Adv. Sci. Res. – volume: 237 start-page: 86 year: 2013 end-page: 95 article-title: New insights into pharmacological profile of LASSBio‐579, a multi‐target N‐phenylpiperazine derivative active on animal models of schizophrenia publication-title: Behav. Brain Res. – volume: 26 start-page: 777 year: 2016 end-page: 797 article-title: Piperazine derivatives for therapeutic use: a patent review (2010‐present) publication-title: Expert Opin. Ther. Pat. – volume: 184 start-page: 49 year: 2016 end-page: 57 article-title: Xylopia aethiopica fruit extract exhibits antidepressant‐like effect via interaction with serotonergic neurotransmission in mice publication-title: J. Ethnopharmacol. – volume: 9 start-page: 155 year: 2010 end-page: 161 article-title: Pathophysiology of depression: do we have any solid evidence of interest to clinicians? publication-title: World Psychiatry. – volume: 28 start-page: 544 year: 2014 end-page: 550 article-title: Cannabidiol reverses the mCPP‐induced increase in marble‐burying behaviour publication-title: Fundam. Clin. Pharmacol. – ident: e_1_2_7_34_1 – ident: e_1_2_7_17_1 doi: 10.1021/jm00153a010 – ident: e_1_2_7_19_1 doi: 10.1016/j.bmcl.2004.05.091 – volume: 91 start-page: 617 year: 2015 ident: e_1_2_7_27_1 article-title: Diagnosis and management of generalized anxiety disorder and panic disorder in adults publication-title: Am. Fam. Physician – ident: e_1_2_7_24_1 doi: 10.1111/fcp.12321 – ident: e_1_2_7_4_1 doi: 10.2174/1386207043328544 – ident: e_1_2_7_20_1 doi: 10.1016/j.ejmech.2012.08.011 – ident: e_1_2_7_22_1 – ident: e_1_2_7_28_1 – ident: e_1_2_7_18_1 doi: 10.1186/1471-244X-14-102 – ident: e_1_2_7_23_1 doi: 10.1192/bjp.bp.115.177261 – ident: e_1_2_7_33_1 – ident: e_1_2_7_10_1 doi: 10.1111/cbdd.12961 – ident: e_1_2_7_13_1 doi: 10.1177/0269881107077260 – volume: 6 start-page: 4145 year: 2015 ident: e_1_2_7_32_1 article-title: Piperazine ‐ A biologically active scaffold publication-title: Int. J. Pharm. Sci. Res. – ident: e_1_2_7_16_1 doi: 10.1016/j.jep.2016.02.023 – ident: e_1_2_7_31_1 doi: 10.1021/jm00091a004 – ident: e_1_2_7_30_1 doi: 10.1007/BF00169129 – ident: e_1_2_7_6_1 doi: 10.1016/j.drugalcdep.2011.10.007 – ident: e_1_2_7_5_1 doi: 10.1080/13543776.2016.1189902 – ident: e_1_2_7_14_1 doi: 10.1007/s00204-013-1057-x – ident: e_1_2_7_8_1 doi: 10.1111/fcp.12051 – ident: e_1_2_7_25_1 doi: 10.1002/j.2051-5545.2010.tb00298.x – volume: 2 start-page: 1547 year: 2011 ident: e_1_2_7_2_1 article-title: Piperazine: the molecule of diverse pharmacological importance publication-title: Int. J. Res. Ayurved. Pharm. – ident: e_1_2_7_7_1 doi: 10.7439/ijasr.v1i1.1766 – ident: e_1_2_7_15_1 doi: 10.1016/j.pbb.2008.12.003 – ident: e_1_2_7_12_1 doi: 10.1016/j.lfs.2015.11.009 – ident: e_1_2_7_29_1 doi: 10.1016/j.brainres.2010.07.007 – ident: e_1_2_7_3_1 doi: 10.2174/138955707782331722 – ident: e_1_2_7_26_1 doi: 10.1155/2013/873278 – ident: e_1_2_7_9_1 doi: 10.1007/s00210-017-1451-7 – ident: e_1_2_7_11_1 doi: 10.1016/j.lfs.2012.04.037 – ident: e_1_2_7_21_1 doi: 10.1016/j.bbr.2012.09.016 |
| SSID | ssj0017016 |
| Score | 2.4797723 |
| SecondaryResourceType | review_article |
| Snippet | Medicinal chemistry is a science applied to the search and discovery of new therapeutic agents for the treatment of various diseases. Therefore, promising... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 13 |
| SubjectTerms | Anti-Anxiety Agents - chemistry Anti-Anxiety Agents - pharmacology Antidepressant Antidepressants Antidepressive Agents - chemistry Antidepressive Agents - pharmacology Antipsychotic Agents - chemistry Antipsychotic Agents - pharmacology Antipsychotics Anxiolytic Buspirone Chemical compounds Chemistry, Pharmaceutical - methods Clozapine Derivatives Drug Discovery - methods Drugs Humans Medical treatment Medicinal chemistry Neuropharmacology Nitrogen atoms Organic chemistry Pharmacology Piperazine Piperazines - chemistry Piperazines - pharmacology Psychotropic drugs Therapeutic applications |
| Title | Piperazine derivatives with central pharmacological activity used as therapeutic tools |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ffcp.12408 https://www.ncbi.nlm.nih.gov/pubmed/30151922 https://www.proquest.com/docview/2168773774 https://www.proquest.com/docview/2095526643 |
| Volume | 33 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3bS-NAFIcPoi_7sl72Yl2VcVlkH0zpZJJJg0-tWmRBKaLiw0KYW0Asbdm0C-5f7zmTS72sIL4FckKSmTknv8yc8w3ADwIMGZNHgZPGBpFwSaDjrgniyFiZhDbVvsr17FyeXkW_buKbJTisa2FKPkQz4Uae4eM1ObjSxSMnz820zQnQhfGXcrVIEF006CjCjPt1ygQDgUi7vKIKURZPc-XTb9ELgflUr_oPzmAVftePWuaZ3LXnM902_55RHN_5LmvwsRKirFeOnHVYcuMN2B-WJOv7A3a5KMwqDtg-Gy4Y1_ef4Hp4O8XzhKZmFgfxX88PLxhN67Iq4ZNNF5fQUGBUQ0FbVbB54SxTBXtU_MVmk8mo-AxXg5PLo9Og2qIhMIJCJU8sT42MlDA6Mbm2qXKJQU2IMRa1ge4oqXKhpIicFdp2UhR8XKNGznNriET_BZbHk7HbBNaRykY8tKqjCYsfaufyONaaWyu1jHkLftadlZmKX07baIyy-j8GWzHzrdiC743ptIR2_M9ou-7xrPLbIgu57CaJQE3cgr3mNHocLaOosZvM0YaofahrItGCr-VIae6C4RIlcRjiw_r-fv322eBo6A-23m76DT6gXkvLpPFtWJ79mbsd1EQzvQsrvf5xf7DrneABrN0Kiw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEB-sPrQvals_ztoaRcQH97jd7GZvwZciHqdVOcpZfJElXwvicXe4d4L-9Z3JfpzWCuLbQiYkm2QmvyQzvwHYJYIhrbPQs0IbL-Q29lTU1l4UaiPiwCTKRbmeX4juZXh6FV3NwWEVC1PwQ9QXbqQZzl6TgtOF9BMtz_S46RND1wdYoIze7kD1uyaPIqJx91IZoyngSdsveYXIj6eu-nw3egExnyNWt-V0luC66mzhaXLbnE5UUz_-w-P43r9ZhsUSi7KfxeL5DHN2-AX2egWZ9cMB689is_IDtsd6M5rrh6_wp3czxnJip2YG1_G9oxDPGd3sstLnk41nVWg1MAqjoGwVbJpbw2TOnsR_scloNMhX4LJz3D_qemWWBk9zspZ-bPxEi1ByrWKdKZNIG2uEhWhmER6olhQy41Lw0BquTCtBzOcrhMlZZjSR0a_C_HA0tOvAWkKa0A-MbClixg-UtVkUKeUbIxTOcAP2q9lKdUlhTpk0Bml1lMFRTN0oNmCnFh0XvB3_E9qspjwtVTdPA1-045gjLG7Adl2MSkcvKXJoR1OUIeI-hDYhb8BasVTqVtBiIioOAuysm_DXm087Rz33sfF20S342O2fn6VnJxe_vsEnhG9J4UO-CfOTu6n9jhBpon44TfgL2wYNNA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3ba9RAFIcPtYL4Uu92tdVRpPjQLJnMZLLBp9K61FsJ0kofhDC3gLTshmZXqH-950wu23oB8S2QGSbJnHPyy-ScbwBeEWDI2kpGXlkXSeGzyKQTG6XSOpUlLjehyvXTkTo8ke9P09M1eNPXwrR8iGHBjTwjxGty8NpVV5y8svWYE6DrBtyUKp6QSR98HthRxBkPPyozjAQin_AOK0RpPEPX6y-j3xTmdcEa3jjTO_C1v9Y20eRsvFyYsf3xC8bxP2_mLmx0SpTttaZzD9b87D7sFC3K-nKXHa8qs5pdtsOKFeT68gF8Kb7VeJ7Y1MyhFX8PAPGG0bou6zI-Wb3qQrbAqIiC9qpgy8Y7pht2pfqLLebz8-YhnEzfHu8fRt0eDZEVFCt55nhuldTCmsxWxuXaZxZFIQZZFAcm1kpXQishvRPGxTkqPm5QJFeVs4SifwTrs_nMbwKLlXaSJ07Hhrj4ifG-SlNjuHPKqJSP4HU_WaXtAOa0j8Z52X_I4FMsw1Mcwcuhad1SO_7UaKuf8bJz3KZMuJpkmUBRPIIXw2l0OfqPomd-vsQ2hO1DYSPFCB63ljKMgvESNXGS4MWG-f778OV0vwgHT_696XO4VRxMy4_vjj48hduo3fI2gXwL1hcXS7-N-mhhngU_-AnNZgvs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Piperazine+derivatives+with+central+pharmacological+activity+used+as+therapeutic+tools&rft.jtitle=Fundamental+%26+clinical+pharmacology&rft.au=Brito%2C+Adriane+F.&rft.au=Moreira%2C+Lorrane+K.+S.&rft.au=Menegatti%2C+Ricardo&rft.au=Costa%2C+Elson+A.&rft.date=2019-02-01&rft.issn=0767-3981&rft.eissn=1472-8206&rft.volume=33&rft.issue=1&rft.spage=13&rft.epage=24&rft_id=info:doi/10.1111%2Ffcp.12408&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_fcp_12408 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0767-3981&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0767-3981&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0767-3981&client=summon |